Nanofármacos

NANOSTRUCTURED LIPID CARRIERS AND STABLE EMULSIONS AND USES THEREOF

Resumen de: US2025241854A1

Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.

METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES

Resumen de: AU2025205348A1

Abstract The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. Hie exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome. Abstract The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. Hie exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome.

MRNA ENCODING INFLUENZA VIRUS-LIKE PARTICLE

Resumen de: AU2023394992A1

The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.

PHARMACEUTICAL FORMULATIONS OF GENE DELIVERY VEHICLES

Resumen de: AU2024209247A1

41 P6105182WOThe invention relates to formulations comprising miRNA that have improved stability for the treatment of diseases including neurodegenerative diseases such as spinocerebellar ataxias type 3. 5

NANOLIPOSOME COMPOSITIONS AND METHODS OF TREATING STROKE

Resumen de: US2025241985A1

Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of stroke.

METHOD FOR PURIFICATION OF LIPID NANOPARTICLES

Resumen de: AU2024223881A1

The present invention relates to methods for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid, comprising the steps of subjecting a solution containing said LNPs to a chromatographic medium with convective flow properties in the presence of at least one kosmotropic agent; and eluting LNPs from said chromatographic medium. The present invention further relates to respective uses of a chromatographic medium with convective flow properties for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid.

IONIZABLE LIPID, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREPARING LIPID NANOPARTICLE

Resumen de: US2025243151A1

An ionizable lipid having a structure represented by the following formula (I):wherein Y is independently selected from a group consisting of —NH—, —O—, —S—, and a single bond; X is independently selected from —NR1R2 or a nitrogen-containing heteroaryl group; L1 and L2 are each independently selected from a group consisting of a C1-C10 alkylene group, a C2-C10 alkenylene group,R1 and R2 are each independently selected from a group consisting of H, a substituted or unsubstituted C1-C10 hydrocarbyl group, a substituted or unsubstituted C1-C10 heterohydrocarbyl group, a substituted or unsubstituted C6-C20 aryl group, and a substituted or unsubstituted C1-C20 heteroaryl group; R3 is a C5-C30 alkyl group; R4 is a C5-C30 alkyl group; n is an integer selected from 1 to 10; and m and p are each independently an integer selected from 1 to 20.

NANOALUM PARTICLES CONTAINING A PEGYLATED LIPID SIZING AGENT

Resumen de: US2025241864A1

Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such a nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

DELIVERY OF THERAPEUTIC RECOMBINANT URICASE USING NANOPARTICLES

Resumen de: US2025241999A1

Systems for enhanced delivery of functional, recombinant soluble uricase enzymes with long serum residence, low immunogenicity and potential for modification have been developed. Compositions and methods of use thereof of nanoparticles including recombinant soluble uricase enzymes are provided for oral administration to a subject. The nanoparticle compositions include recombinant soluble uricase enzymes that are not PEGylated, and have a serum residence time of hours, days or weeks following oral administration. A reduced level of side effects of the formulation provides an effective and safe drug delivery platform for treating Tumor Lysis syndrome and Lesch-Nyhan disease, as well as hyperuricemia and associated diseases or disorders.

NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY

Resumen de: AU2024206838A1

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject that, optionally, have reduced reactogenicity and promotes a local innate immune response in the subject while promoting an adaptive immune response. Compositions described herein include nanoparticles, optionally including an inorganic particle, capable of admixing with nucleic acids encoding proteins, antibodies, or immunomodulators. Methods of using the compositions as a therapeutic vaccine for the treatment of an infection or cancer are also provided.

LIPID NANOPARTICLE FOR RADIATION THERAPY, MANUFACTURING METHOD, COMBINATION COMPOSITION, AND KIT

Resumen de: EP4591890A1

According to one arrangement, a radiotherapy lipid nanoparticle (10) includes a biodegradable lipid nanoparticle (11), and a radioactive material (12) as an active ingredient. The radioactive material is bound to the biodegradable lipid nanoparticle and located outside of the biodegradable lipid nanoparticle.

LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO

Resumen de: MX2025003345A

Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA). The LNP comprises at least a cationic lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the LNP comprises at least one glycerol dialkyl glycerol tetraether (GDGT) lipid, as obtained e.g. from archaea of the genus Sulfolobus, optionally among other ether lipids. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine.

OIL-IN-WATER EMULSIONS FOR TOPICAL ADMINISTRATION AND USES THEREOF

Resumen de: WO2024062127A1

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).

FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS

Resumen de: WO2024061861A1

The present invention relates to a composition comprising a solid carrier, an enzyme or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the enzyme or the fragment thereof by embedding the enzyme or the fragment thereof, and a functional constituent immobilized on the surface of the protective layer. The present invention also relates to a method for the prevention, delay of progression or treatment of lung cancer in a subject using said composition and methods of producing said composition.

ANTIVIRAL SIRNA THERAPEUTIC FOR SARS-COV-2

Resumen de: AU2023347083A1

This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.

LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS ENCODING THERAPEUTIC GENES AND USES IN MEDICAL METHODS

Resumen de: WO2024064206A1

This disclosure relates to lipid nanoparticles comprising nucleic acids encoding therapeutic proteins and uses in treating diseases such as cancer. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of lipid nanoparticles as reported herein comprising a vector or nucleic acid encoding peptide based anticancer agent.

LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF

Resumen de: WO2024064800A2

Disclosed herein are lipid nanoparticles comprising plurality of lipids, a targeting moiety for an HIV-1 chemokine receptor, and a CRISPR nucleic acid complementary to an HIV-1 gene, pharmaceutical compositions and methods of use thereof.

POLYMER NANOPARTICLES OF METABOLITES AND USE THEREOF

Resumen de: EP4591856A1

The present disclosure relates to polymer nanoparticles of metabolites, a cell activity promotion method using same, and a cell activity promotion composition including same. In particular, the present disclosure relates to a method and a composition, for promoting, by the permeation of polymer nanoparticles of metabolites into cells, the activities of cells, for example, adhesion between cells or between tissues, hemostasis, wound healing promotion, hair root regeneration activity, and antibacterial activity.

LIPID NANOPARTICLE, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: EP4591859A1

The invention discloses a lipid nanoparticle and a preparation method and application thereof are provided. The lipid nanoparticle (LNP) includes a carrier and an encapsulated nucleic acid, the carrier includes an ionizable lipid, a helper phospholipid, a PEGylated lipid, cholesterol and its derivatives, and a retinoid compound; and the nucleic acid is one or more of mRNA, circRNA, siRNA, microRNA, antisense nucleic acid, and plasmid. The invention proves that the five-component LNP can activate the triple immune response of body fluid, cells and mucosa after intramuscular or subcutaneous administration, and has important application prospects in the field of infectious disease vaccines and mucosal-related tumor vaccines.

NOVEL SECRETORY SIGNAL PEPTIDES

Resumen de: AU2023347284A1

Provided here are novel engineered and isolated signal peptide sequences and compositions comprising these. Also provided are compositions and methods of using these signal peptides to enable secretion of heterologous polypeptides for therapeutic, diagnostic, and commercial value.

一种含有Survivin siRNA和ZnO的pH敏感的靶向纳米载药系统

Resumen de: CN120381440A

本发明公开了具有pH响应性和肿瘤靶向性的siRNA递送载体CCM‑CS/ZnO@siSurvivin，公开了其制备方法，公开了其形态、结构等理化性质，公开了其包封率、释药行为，公开了其细胞摄取效率、肿瘤靶向能力、溶酶体逃逸能力、基因沉默效率、促凋亡能力、肿瘤细胞生长抑制能力，公开了Survivin siRNA和ZnO协同抗肿瘤能力，进一步公开了其体内靶向性以及抑制BALB/c荷瘤裸鼠肿瘤生长的作用和体内安全性。进而阐明了该靶向递送载体在肿瘤的基因治疗领域具有重要的应用。

用于器官选择性递送核酸药物的类脂质分子、类脂质纳米颗粒及其应用、类脂质纳米颗粒-核酸复合物及其制备方法

Resumen de: CN120383729A

本发明涉及生物医药技术领域，尤其涉及一种用于器官选择性递送核酸药物的类脂质分子、类脂质纳米颗粒及其应用、类脂质纳米颗粒‑核酸复合物及其制备方法。本发明提供的类脂质分子是由聚乙烯亚胺与芳基丙烯酸酯发生迈克尔加成反应得到，合成方法简单安全，反应条件温和，成本低；所述类脂质纳米颗粒按质量百分比计由如下组分组成：类脂质分子30～80％，甾醇5～50％，聚乙二醇‑脂质5～40％，辅助脂质5～50％。本发明的优点在于通过调节类脂质分子自身的化学结构实现了其类脂质纳米颗粒在受试生物体内对核酸药物的器官选择性递送。

环状RNA组合物

Resumen de: AU2023375897A1

Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treatment, including for cancer and autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder, a HER2 binder, or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.

一种载药纳米粒子及金属多酚网络介导的可食源性组装体

Resumen de: CN120381531A

本发明涉及载药粒子技术领域，尤其涉及一种载药纳米粒子及金属多酚网络介导的可食源性组装体，将天然硫化物包覆在含有介孔结构的碳酸钙中形成所述载药纳米粒子，并将载药纳米粒子的外层包裹上具有金属‑多酚网络结构的纳米涂层，得到金属多酚网络介导的可食源性组装体，用于制备治疗酒精损伤的药物，所述药物有助于减轻酒精造成的组织损伤和行为障碍。

一种可溶性纳米微针及其制备方法和应用

Nº publicación: CN120381429A 29/07/2025

Solicitante:

四川华琢生物科技有限公司

Resumen de: CN120381429A

本发明公开了一种可溶性纳米微针及其制备方法和应用，涉及纳米微针领域。本发明在制备可溶性纳米微针时，将吡咯、苯甲醛、对羟基苯甲醛、1,6‑二溴己烷反应制得季铵化卟啉；将聚乳酸‑羟基乙酸共聚物、季铵化卟啉通过乳液法制得载药纳米微球；再将聚乙烯醇溶液、载药纳米微球通过模板法制得。本发明制备的可溶性纳米微针具有良好的药物释放效果，药物利用率高，且刺激性低。